VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
EOCN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
EOCNEocene Ltd.
$2.46$3M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksEOCNFinancials

Eocene Ltd. (EOCN) Income Statement

14Y historyFree accessUpdated daily

With zero revenue and zero gross profit across all reported quarters, the income statement shows operating losses widening from -$1.2M in 2024Q2 to -$2.8M in 2026Q2 with no margin base to evaluate.

Income StatementBalance SheetCash FlowRatios

EOCN Income Statement

Annual statement

EOCN Income Statement

Eocene Ltd. (EOCN) annual income statement — 14-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Sales/Revenue000000002.04M1.08M467K0000
Revenue Growth %--------100%87.83%132.33%-----
Cost of Goods Sold0000000000050K9K4K5K
COGS % of Revenue---------------
Gross Profit000000002.04M1.08M467K-50K-9K-4K-5K
Gross Margin %--------100%100%100%----
Gross Profit Growth %--------100%87.83%132.33%1034%-455.56%-125%20%-
Operating Expenses9.96M8.51M6.28M7.49M17.65M32.88M30.21M22.38M12.75M13.45M17.35M10.82M9.13M14.56M3.13M
OpEx % of Revenue--------625.76%1239.54%3714.99%----
Selling, General & Admin3.63M3.64M3.3M3.92M4.66M5.66M4.13M4.2M4.44M3.8M3.08M3.2M2.47M7.35M689K
SG&A % of Revenue--------217.86%350.14%659.1%----
Research & Development6.32M4.87M2.98M3.57M12.99M27.22M26.08M18.18M8.31M9.65M14.27M7.63M6.66M7.21M2.44M
R&D % of Revenue--------407.9%889.4%3055.89%----
Other Operating Expenses000000000000000
Operating Income-9.96M-8.51M-6.28M-7.49M-17.65M-32.88M-30.21M-22.38M-10.71M-12.36M-16.88M-10.88M-9.14M-14.56M-3.14M
Operating Margin %---------525.76%-1139.54%-3614.99%----
Operating Income Growth %--35.55%16.2%57.55%46.32%-8.84%-35.01%-108.83%13.34%26.76%-55.24%-18.96%37.22%-364.2%-
EBITDA-11.53M-10.31M-6.2M-7.46M-17.62M-32.84M-30.17M-22.34M-10.33M-12.13M-16.71M-10.82M-9.13M-14.56M-3.13M
EBITDA Margin %---------506.77%-1117.51%-3578.8%----
EBITDA Growth %-39.34%-66.41%16.97%57.65%46.36%-8.84%-35.05%-116.31%14.82%27.45%-54.39%-18.53%37.26%-364.81%-
D&A (Non-Cash Add-back)0083K31K35K42K39K35K387K239K169K50K9K4K5K
EBIT-11.53M-10.31M-7.5M-6.9M-17.65M-32.42M-30.21M-22.38M-10.71M-12.36M-16.88M-10.88M-9.14M-14.56M-3.14M
Net Interest Income800K914K488K364K82K519K1.16M1.88M917K153K315K00-34K6
Interest Income902K914K503K375K297K562K1.19M1.92M959K65K35K253K40K06
Interest Expense102K015K11K215K43K31K33K42K49K67K0034K0
Other Income/Expense-1.39M-1.8M-1.24M580K-215K414K1.44M1.92M934K65K35K253K40K-2.92M-6K
Pretax Income-11.34M-10.31M-7.52M-6.91M-17.87M-32.47M-28.77M-20.46M-9.78M-12.3M-16.85M-10.62M-9.1M-17.48M-3.14M
Pretax Margin %---------479.93%-1133.55%-3607.49%----
Income Tax0000000075K0106K01K1K6K
Effective Tax Rate %0%0%0%0%0%0%0%0%-0.77%0%-0.63%0%-0.01%-0.01%-0.19%
Net Income-11.34M-10.31M-7.52M-6.91M-17.87M-32.47M-28.77M-20.46M-9.86M-12.3M-16.95M-10.62M-9.1M-17.48M-3.15M
Net Margin %---------483.61%-1133.55%-3630.19%----
Net Income Growth %-30.05%-37.14%-8.75%61.31%44.97%-12.85%-40.61%-107.6%19.86%27.45%-59.6%-16.69%47.94%-455.26%-
Net Income (Continuing)-11.34M-10.31M-7.52M-6.91M-17.87M-32.47M-28.77M-20.46M-9.86M-12.3M-16.95M-10.62M-9.1M-17.48M-3.15M
Discontinued Operations000000000000000
Minority Interest000000000000000
EPS (Diluted)-11.91-19.12-64.64-239.60-88.64-155.84-155.68-105.36-65.20-118.16-178.88-14.35-13.23-24.57-9.32
EPS Growth %97.71%70.42%73.02%-170.31%43.12%-0.1%-47.76%-61.6%44.82%33.94%-1146.55%-8.47%46.15%-163.63%-
EPS (Basic)--19.12-64.64-240.40-88.64-155.84-155.68-105.36-65.20-118.16-178.88-14.35-13.23-24.57-9.32
Diluted Shares Outstanding952.17K538.91K116.35K28.85K209.52K204.98K177.34K175.95K151.15K104.06K94.79K740.03K688.25K711.66K337.96K
Basic Shares Outstanding952.17K538.91K116.35K28.75K209.52K204.98K177.34K175.95K151.15K104.06K94.79K740.03K688.25K711.66K337.96K
Dividend Payout Ratio---------------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetMixed
Cash FlowMixed
Top Statement Risk

Persistent operating losses without revenue

Pre-Revenue Profile With No Top-Line Base

Based on EOCN's reported quarterly figures, no revenue or cost of goods sold has been recorded across the ten quarters from 2024Q1 through 2026Q2, leaving growth-rate analysis unavailable for the period.

The absence of reported revenue means revenue growth cannot be measured, and the income statement reflects a development-stage cost base rather than a commercial operation. This suggests the company's economics currently depend on R&D progress and external funding rather than sales traction. Investors should monitor for any first revenue recognition, which would be the first observable test of commercial viability.

R&D-Led Spending Shapes the Loss Profile

As reported in EOCN's quarterly statements, R&D expense rose from $534.0K in 2024Q2 to $1.8M in 2026Q2, becoming the dominant operating cost line in recent periods.

R&D has grown faster than SG&A over the recent window, with SG&A ranging roughly between $572K and $1.3M without a clear trend. This pattern suggests spending is being directed toward clinical or technical development rather than commercial infrastructure. Whether this allocation is appropriate depends on pipeline milestones that the income statement alone cannot confirm.

Operating Losses Show No Scaling Benefit

Based on EOCN's reported figures, operating loss widened from -$1.2M in 2024Q2 to -$2.8M in 2026Q2 with no gross profit offset, indicating no operating leverage is yet observable.

With gross profit at zero, operating leverage in the conventional sense cannot be assessed, and the cost base has expanded rather than being absorbed by revenue. The recent quarters show losses roughly doubling against the early-period baseline. This may indicate that cost growth is outpacing any path to commercial scale, warranting further investigation of spending guidance.

Share Count Volatility Distorts Per-Share Losses

According to reported EPS, diluted loss per share swung from -$1.84 in 2024Q1 to -$371.36 in 2024Q4, a movement that appears driven by share count changes rather than operating performance alone.

Net loss figures moved within a comparatively narrow range while EPS varied enormously, suggesting material changes in the share base, possibly from reverse splits or capital raises. Such variability makes per-share trend analysis unreliable for this period. Investors should examine share count disclosures before drawing conclusions from EPS trajectory.

Sustained Losses Could Erode Funding Runway

Based on reported figures, cumulative quarterly net losses across the ten periods exceed $20M while revenue remains zero, raising questions about how long current resources can sustain operations without additional capital.

The counter-argument is that the company may be forced into dilutive financing, which the EPS volatility already hints at. Stock-based compensation of roughly $100K to $240K per quarter adds a non-cash cost but does not change the underlying cash burn implication. Without disclosed cash balances in the supplied data, the funding risk remains an inference that warrants verification against the balance sheet.

EOCN — Frequently Asked Questions

Quick answers to the most common questions about buying EOCN stock.

What was Eocene Ltd.'s (EOCN) revenue in 2025?

For fiscal year 2025, Eocene Ltd. (EOCN) reported total revenue of $0.0M.

Is Eocene Ltd. (EOCN) profitable?

Eocene Ltd. (EOCN) reported a net loss of $10.3M for the fiscal year ending 2025.